TrialAnnals of hematology2025

Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.

Weijun Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.